Alliance Pharma plc (AIM:APH)

Market Cap	356.51M
Revenue (ttm)	178.84M
Net Income (ttm)	-10.73M
Shares Out	551.02M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	13.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,690,270
Average Volume	4,303,124
Open	64.80
Previous Close	64.70
Day's Range	64.60 - 64.80
52-Week Range	24.55 - 66.20
Beta	0.58
RSI	71.62
Earnings Date	Jun 26, 2025

About Alliance Pharma

Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom. As of May 14, 2025, Alliance Pharma plc was taken private.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 290
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: APH

Financial Performance

In 2024, Alliance Pharma's revenue was 178.84 million, a decrease of -1.02% compared to the previous year's 180.68 million. Losses were -10.73 million, -67.62% less than in 2023.